Lv73
4810 积分 2021-07-02 加入
Discovery and characterization of orally active FGFR3-selective small-molecule inhibitors for urothelial carcinoma
2天前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
7天前
已完结
Small molecule approaches to treat autoimmune and inflammatory diseases (Part III): Targeting cytokines and cytokine receptor complexes
25天前
已完结
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
1个月前
已完结
Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis
1个月前
已完结
Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
1个月前
已完结
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
1个月前
已完结
Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review
2个月前
已完结
Emerging trends in permeation-enhancing technologies for oral peptide delivery
2个月前
已完结
Engineering Peptides for Oral Delivery: Structural Design, Barrier Modulation, and Emerging Therapeutic Technologies
2个月前
已完结
皖公网安备34019202002308
